683 Capital Management’s ADMA Biologics ADMA Stock Holding History

683 Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-222,603	Closed	-$407K	–	269
2022 Q1	$407K	Sell	222,603 -81,208	-27%	-$127K	0.02%	197
2021 Q4	$428K	Buy	+303,811	New	+$399K	0.02%	217
2021 Q1	–	Sell	-2,000,000	Closed	-$3.9M	–	171
2020 Q4	$3.9M	Hold	2,000,000	–	–	0.18%	79
2020 Q3	$4.78M	Hold	2,000,000	–	–	0.35%	54
2020 Q2	$5.86M	Hold	2,000,000	–	–	0.47%	47
2020 Q1	$5.76M	Buy	2,000,000 +1,300,000	+186%	+$4.49M	0.68%	36
2019 Q4	$2.8M	Sell	700,000 -724,378	-51%	-$3.16M	0.32%	54
2019 Q3	$6.34M	Hold	1,424,378	–	–	0.7%	36
2019 Q2	$5.51M	Buy	1,424,378 +619,378	+77%	+$2.73M	0.5%	48
2019 Q1	$3.05M	Hold	805,000	–	–	0.28%	68
2018 Q4	$1.92M	Hold	805,000	–	–	0.12%	91
2018 Q3	$5M	Sell	805,000 -80,000	-9%	-$461K	0.32%	56
2018 Q2	$3.99M	Buy	885,000 +80,000	+10%	+$399K	0.27%	63
2018 Q1	$3.7M	Sell	805,000 -145,000	-15%	-$576K	0.33%	63
2017 Q4	$3.05M	Buy	+950,000	New	+$2.66M	0.26%	77

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

683 Capital Management's ADMA Position: Q2 2022 in Review

683 Capital Management sold out of ADMA Biologics (ADMA) in Q2 2022, closing a stake of 222,603 shares — an estimated $407K sold.

683 Capital Management first reported a position in ADMA in Q4 2017 and held it in 15 quarters. The position peaked at $6.34M in Q3 2019. 113 funds tracked by Wall St. Rank hold ADMA as of Q2 2022.

683 Capital Management reported no remaining ADMA Biologics position as of Q2 2022 after selling out during the quarter.
683 Capital Management sold 222,603 ADMA Biologics shares in Q2 2022, an estimated $407K.
683 Capital Management first reported a position in ADMA Biologics in Q4 2017 and held it in 15 quarters.
683 Capital Management's ADMA Biologics position peaked at $6.34M in Q3 2019.
113 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2022.

Based on 683 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.